A Clinical Study of GRC 8200 in Type 2 Diabetes Mellitus

Summary

The study is aimed at evaluating efficacy and safety of GRC 8200 in type 2 diabetes mellitus patients. The study involves six weeks of wash out period and two weeks run in period for patients currently on mono-therapy and a two week run in period only for drug naïve patients. This is a placebo controlled study. One of the five treatment arms is placebo. The duration of treatment is 12 weeks.

Timeline

Start

2008-06

Primary completion

2009-05

Completion

2009-10

Drugs

Indications